Amgen investing $300 million to expand facility in Juncos.

By THE STAR STAFF

Amgen is investing an additional $300 million to expand its biologics manufacturing facility in Juncos, deepening a decades‑long presence on the island and reinforcing its role in the company’s global supply chain.

According to MarketWatch, the new investment will support production scale‑up, the integration of advanced manufacturing technologies, and efforts to ensure an uninterrupted supply of medicines. The expansion is also expected to create new jobs, including construction roles, highly skilled manufacturing positions, and opportunities tied to local workforce development initiatives.

The latest commitment builds on Amgen’s $650 million investment announced last year, which was projected to generate roughly 750 jobs. With Monday’s announcement, the company’s recent capital commitments in Puerto Rico approach $1 billion. Medicines produced at the Juncos site are distributed to patients in more than 60 countries, and the campus ranks among the largest biologics manufacturing facilities in the world.

Amgen’s footprint in Puerto Rico dates back more than three decades. The company established its Juncos manufacturing operation in the early 1990s as it transitioned from small‑scale clinical production to large‑scale commercial manufacturing of biologic therapies. What began as a single building with a small workforce has since grown into a multi‑building manufacturing complex employing thousands, supporting the production of more than two dozen medicines across multiple therapeutic areas.

The expansion in Puerto Rico comes as part of a broader push by global drugmakers to increase domestic manufacturing capacity amid rising trade pressures. Under an executive order issued by President Donald Trump in April, branded pharmaceuticals imported into the U.S. could face tariffs of up to 100% unless manufacturers either enter into government drug‑pricing agreements or shift production to U.S.‑based facilities.

Beyond Puerto Rico, Amgen has announced significant U.S. investments in recent months, including a $600 million science and innovation center in California, more than $1.5 billion in North Carolina, and $900 million in manufacturing expansion in Ohio, underscoring a company‑wide strategy to strengthen its domestic manufacturing network.